Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Exhaustive drug repurposing strategies support the pursuit of new chemical entities for the development of effective COVID-19 interventions

ABSTRACT: Exhaustive drug repurposing strategies support the pursuit of new chemical entities for the development of effective COVID-19 interventions

PROVIDER: PRJNA706017 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13833624_1.fastq.gz	Fastqsanger.gz
	SRR13833624_2.fastq.gz	Fastqsanger.gz
	SRR13833625_1.fastq.gz	Fastqsanger.gz
	SRR13833625_2.fastq.gz	Fastqsanger.gz
	SRR13833626_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Exhaustive drug repurposing strategies support the pursuit of new chemical entities for the development of effective COVID-19 interventions

Project description:The ongoing pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), necessitates strategies to identify prophylactic and therapeutic drug candidates for rapid clinical deployment. Here we describe a screening pipeline for the discovery of efficacious SARS-CoV-2 inhibitors. Two high-throughput, high-content imaging infection assays (one using HeLa cells expressing SARS-CoV-2 receptor ACE2 and the other using lung epithelial Calu-3 cells) were developed and used to screen ReFRAME, a best-in-class drug repurposing library. Among the promising hits, the antivirals nelfinavir and the parent of prodrug MK-4482 had most favorable in vitro activity, pharmacokinetic and human safety profiles, and both reduced SARS-CoV-2 replication in an orthogonal human differentiated primary cell model. However, only MK-4482 effectively blocked SARS-CoV-2 infection in a hamster model, likely due to inadequate plasma exposure of nelfinavir.

2021-04-02 | GSE168095 | GEO

Machine Learning Identifies Candidates for Drug Repurposing in Alzheimer's Disease

Project description:Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. In this study, we profile 80 FDA-approved and clinically tested drugs in neural cell cultures, with the goal of producing a ranked list of possible repurposing candidates.

2021-01-14 | GSE164788 | GEO

Exhaustive screening of outer hair cell-specific genes

Project description:Exhaustive screening of outer hair cell-specific genes

| PRJNA497334 | ENA

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [Tissue_RNA-seq]

Project description:we present a novel path to drug repurposing to identify new immunotherapies for ASCVD. The integration of time of-flight mass cytometry (CyTOF) and RNA-sequencing identified unique inflammatory signatures in peripheral blood mononuclear cells (PBMCs) stimulated with ASCVD plasma. By comparing these inflammatory signatures to large-scale gene expression data from the LINCS L1000 dataset, we identified drugs that could reverse this inflammatory response. In conclusion, a systems immunology-driven drug repurposing with pre- clinical validation strategy can aid the development of new cardiovascular immunotherapies.

2023-04-23 | GSE230216 | GEO

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [DRUG_RNA-seq]

2023-04-23 | GSE230215 | GEO

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [RNA-seq_PBMC]

2023-04-23 | GSE230214 | GEO

Nutritional and Pharmaceutical Interventions in Diabetic Rats

Project description:Nutritional and Pharmaceutical Interventions in Diabetic Rats

| PRJNA360905 | ENA

Repurposing bioactive aporphine alkaloids as efflux pump inhibitors

Project description:Repurposing bioactive aporphine alkaloids as efflux pump inhibitors

| PRJNA416141 | ENA

Repurposing of promoters and enhancers during mammalian evolution